Small molecule therapeutics targeting F-box proteins in cancer

Semin Cancer Biol. 2016 Feb:36:105-19. doi: 10.1016/j.semcancer.2015.09.014. Epub 2015 Sep 30.

Abstract

The ubiquitin proteasome system (UPS) plays vital roles in maintaining protein equilibrium mainly through proteolytic degradation of targeted substrates. The archetypical SCF ubiquitin E3 ligase complex contains a substrate recognition subunit F-box protein that recruits substrates to the catalytic ligase core for its polyubiquitylation and subsequent proteasomal degradation. Several well-characterized F-box proteins have been demonstrated that are tightly linked to neoplasia. There is mounting information characterizing F-box protein-substrate interactions with the rationale to develop unique therapeutics for cancer treatment. Here we review that how F-box proteins function in cancer and summarize potential small molecule inhibitors for cancer therapy.

Keywords: Cancer; E3 ligase; F-box protein; Small molecule inhibitor; Ubiquitin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • F-Box Proteins / antagonists & inhibitors*
  • F-Box Proteins / metabolism*
  • Humans
  • Molecular Targeted Therapy*
  • Multiprotein Complexes / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Proteasome Endopeptidase Complex / metabolism
  • Protein Binding
  • Signal Transduction / drug effects
  • Ubiquitins / antagonists & inhibitors
  • Ubiquitins / metabolism

Substances

  • Antineoplastic Agents
  • F-Box Proteins
  • Multiprotein Complexes
  • Ubiquitins
  • Proteasome Endopeptidase Complex